Document is current
Any future updates will be listed below
-
Authors
Rofail, Diana
Hussein, Mohamed
Naumann, Ulrike
Podolanczuk, Anna J.
Norton, Thomas
Ali, Shazia
Mastey, Vera
Ivanescu, Cristina
Hirshberg, Boaz
Geba, Gregory P.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04425629 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-Reported Outcomes in COVID-19 Treatment with Monoclonal Antibodies Reveal Benefits in Return to Usual Activities
https://doi.org/10.1007/s40121-024-01013-1
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
https://doi.org/10.1136/bmjopen-2024-087431
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
Administration for Strategic Preparedness and Response (HHSO100201800036C)
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 21 June 2024
First Online: 3 July 2024
Declarations
:
: Diana Rofail is an employee/stockholder of Regeneron Pharmaceuticals, Inc. and former employee and stockholder of F. Hoffmann-La Roche AG. Mohamed Hussein, Thomas Norton, Shazia Ali, Vera Mastey, Boaz Hirshberg, and Gregory P. Geba are employees/stockholders of Regeneron Pharmaceuticals, Inc. Ulrike Naumann and Cristina Ivanescu are employees of IQVIA and received consultancy fees from Regeneron Pharmaceuticals, Inc. Anna J. Podolanczuk received consultancy fees from Regeneron Pharmaceuticals, Inc., received honoraria from NACE (CME), and has participated in an advisory board for Boehringer Ingelheim.
: The trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and all applicable regulatory requirements []. The local institutional review board or ethics committee at each trial site monitored trial conduct and documentation. Data were reported according to CONSORT-PRO guidelines. All patients provided written informed consent [].
